% | $
Quotes you view appear here for quick access.

RXi Pharmaceuticals Corporation Message Board

  • red900901 red900901 Mar 8, 2013 1:05 PM Flag

    "Opko Health sells RNA projects to RXi, stock hits new high"


    Brian bandell
    Senior Reporter- South Florida Business Journal

    Opko Health has agreed to sell its in RNA interference research products to RXi Pharmaceuticals Corp., prompting investors to push its stock to a new high.

    Miami-based Opko (NYSE: OPK) will give the Westborough, Mass.-based company (OTCBB: RXII) an intellectual property portfolio that includes 12 families of patents. RNA interference is designed to suppress the expression of specific genes that are linked to diseases. Opko’s RNAi products were being developed for the treatment of eye disease, cancer, immune disorders and inflammatory diseases.

    In return, Opko would receive 50 million shares of RXi and could receive up to $50 million in milestone payments, based on the progress of the products that were sold. Opko would also receive a royalty payment upon the commercialization of those products.

    Shares of RXi closed Wednesday at 14.5 cents, so 50 million shares were worth $7.25 million.

    RXi also announced it will raise $16.4 million through a private placement of 113 million shares at 14.5 cents each. That financing was led by Opko and Frost Gamma Investments Trust, which is led by Opko Chairman and CEO Dr. Phillip Frost.

    “RXi has contributed a major advance to the RNAi field with its self-delivering RNAi technology,” Frost said in a news release. “This technology overcomes a major delivery obstacle of prior RNAi technologies by significantly enhancing the uptake of the gene-targeting drug into cells. We also are impressed with RXi’s development capabilities, as evidenced by its rapid advancement of RXI-109, an exciting product candidate for the potential treatment of dermal scarring.”

    Continued --

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The cennection factor between OPK and now RXII is Dr. PHILLIP FROST a billionar pharma investor . DR Frost owns 40% of OPK stock on the market . On thursday RXII sold 16 million dollars of share to private investors . My bet it was Dr Frost , or Frost-Gamma his trust , that got those shares . Another company Dr Frost has bought over 10% of in the last 4 months is a small Pharma called ALQA that has 2 products on the maeket that are small molecule dressings for scarring and wound care after surgery . Dosent that sound a little like RXII s products . I think that in the future months that ALQA and RXII will merge , or one will buy the other . Or OPK could buy them both and combine them in-house . I have shares in all 3 companys . Good luck to all .

      Sentiment: Strong Buy

0.500.00(+0.99%)May 22 4:00 PMEDT